{"id":70608,"date":"2026-07-24T21:11:39","date_gmt":"2026-07-24T13:11:39","guid":{"rendered":"https:\/\/flcube.com\/?p=70608"},"modified":"2026-07-24T21:11:40","modified_gmt":"2026-07-24T13:11:40","slug":"kanghong-pharmaceutical-secures-nmpa-approval-for-khn921-gene-therapy-in-mybpc3-related-hypertrophic-cardiomyopathy-following-u-s-fda-clearance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70608","title":{"rendered":"Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Kanghong Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/002773:SHE\">SHE: 002773<\/a>) announced on <strong>July 23, 2026<\/strong> that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>KHN921<\/strong> for clinical trials in patients with <strong>hypertrophic cardiomyopathy (HCM) caused by MYBPC3 mutations<\/strong>. The investigational therapy represents Kanghong&#8217;s first <strong>AAV-based gene therapy product<\/strong>, utilizing an adeno-associated virus (AAV) vector to deliver a functional gene directly to cardiomyocytes, addressing the disease at its genetic root. This regulatory milestone follows <strong>U.S. FDA clinical trial approval<\/strong> granted in April 2026, positioning KHN921 as a globally developed gene therapy candidate.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Kanghong Pharmaceutical (SHE: 002773)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>KHN921 (AAV-based gene therapy)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Hypertrophic cardiomyopathy caused by MYBPC3 mutations<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>23 Jul 2026<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>U.S. FDA clinical trial approval (April 2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Platform:<\/strong> <strong>AAV-based gene therapy<\/strong> utilizing adeno-associated virus vector for targeted cardiac delivery<\/li>\n\n\n\n<li><strong>Genetic Targeting:<\/strong> Delivers a <strong>functional MYBPC3 gene<\/strong> to cardiomyocytes to correct functional defects caused by pathogenic mutations<\/li>\n\n\n\n<li><strong>Disease Modification:<\/strong> Aims to address HCM at the <strong>genetic level<\/strong> rather than managing symptoms, representing a potential curative approach<\/li>\n\n\n\n<li><strong>Therapeutic Goals:<\/strong> Improve myocardial structure and function, delay or reverse disease progression, and reduce risk of serious cardiovascular events including sudden cardiac death<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-scientific-rationale-amp-clinical-significance\" class=\"wp-block-heading\">Scientific Rationale &amp; Clinical Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MYBPC3 Mutations:<\/strong> Account for approximately <strong>40-50% of all HCM cases<\/strong>, making this the most common genetic cause of the disease<\/li>\n\n\n\n<li><strong>Unmet Medical Need:<\/strong> Current HCM treatments focus on symptom management and do not address the underlying genetic defect, leaving significant unmet need for disease-modifying therapies<\/li>\n\n\n\n<li><strong>Gene Therapy Advantage:<\/strong> Single-dose administration could provide <strong>long-term or permanent correction<\/strong> of the genetic defect, potentially eliminating the need for chronic medication<\/li>\n\n\n\n<li><strong>Cardiac Targeting:<\/strong> AAV vector engineered for <strong>cardiomyocyte-specific delivery<\/strong> to maximize therapeutic effect while minimizing off-target exposure<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-global-development-strategy\" class=\"wp-block-heading\">Global Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Regulatory Path:<\/strong> Simultaneous development in <strong>U.S. and China<\/strong> demonstrates Kanghong&#8217;s global ambitions and confidence in the therapy&#8217;s potential<\/li>\n\n\n\n<li><strong>Regulatory Alignment:<\/strong> NMPA approval following FDA clearance suggests consistent regulatory requirements and scientific validation across major markets<\/li>\n\n\n\n<li><strong>Clinical Trial Design:<\/strong> Likely to employ similar protocols in both regions to facilitate global data integration and potential simultaneous regulatory submissions<\/li>\n\n\n\n<li><strong>Manufacturing Scale:<\/strong> AAV gene therapy production requires specialized manufacturing capabilities, indicating significant investment in technical infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HCM Prevalence:<\/strong> Affects approximately <strong>1 in 500 people globally<\/strong>, with MYBPC3-related cases representing the largest genetic subgroup<\/li>\n\n\n\n<li><strong>Premium Pricing Potential:<\/strong> Gene therapies typically command <strong>multi-million dollar price tags<\/strong> due to curative potential and single-dose administration<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Would be among the first gene therapies specifically targeting MYBPC3-related HCM, with limited direct competition in the genetic HCM space<\/li>\n\n\n\n<li><strong>Addressable Population:<\/strong> Estimated <strong>200,000-300,000 MYBPC3-HCM patients in China<\/strong> alone, representing substantial commercial opportunity<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-kanghong\" class=\"wp-block-heading\">Strategic Implications for Kanghong<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> Success with KHN921 would validate Kanghong&#8217;s <strong>gene therapy platform<\/strong>, enabling expansion into other monogenic cardiovascular and neurological diseases<\/li>\n\n\n\n<li><strong>Innovation Leadership:<\/strong> Positions Kanghong as a pioneer in <strong>Chinese gene therapy development<\/strong>, moving beyond traditional small molecules and biologics<\/li>\n\n\n\n<li><strong>Global Partnerships:<\/strong> Strong clinical data could attract international partnership interest from larger pharmaceutical companies seeking gene therapy capabilities<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> Adds high-value gene therapy modality to Kanghong&#8217;s existing portfolio of ophthalmology, oncology, and CNS products<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-investment-considerations\" class=\"wp-block-heading\">Investment Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High-Risk, High-Reward:<\/strong> Gene therapy development carries significant technical and regulatory risks but offers transformative commercial potential upon success<\/li>\n\n\n\n<li><strong>Capital Intensity:<\/strong> AAV manufacturing and clinical development require substantial investment, potentially impacting near-term cash flow<\/li>\n\n\n\n<li><strong>Regulatory Premium:<\/strong> First-in-class gene therapies for rare genetic diseases often receive expedited regulatory pathways and extended market exclusivity<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Even partial success could significantly enhance Kanghong&#8217;s valuation and position in China&#8217;s innovative biopharmaceutical sector<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to clinical trial outcomes, manufacturing challenges, and regulatory decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced on July 23, 2026 that China&#8217;s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,66,653,24,1335],"class_list":["post-70608","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-gene-therapy","tag-kanghong-pharmaceutical","tag-rare-orphan-disease-drugs","tag-she-002773"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced on July 23, 2026 that China&#039;s National Medical Products Administration (NMPA) has approved KHN921 for clinical trials in patients with hypertrophic cardiomyopathy (HCM) caused by MYBPC3 mutations. The investigational therapy represents Kanghong&#039;s first AAV-based gene therapy product, utilizing an adeno-associated virus (AAV) vector to deliver a functional gene directly to cardiomyocytes, addressing the disease at its genetic root. This regulatory milestone follows U.S. FDA clinical trial approval granted in April 2026, positioning KHN921 as a globally developed gene therapy candidate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70608\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance\" \/>\n<meta property=\"og:description\" content=\"Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced on July 23, 2026 that China&#039;s National Medical Products Administration (NMPA) has approved KHN921 for clinical trials in patients with hypertrophic cardiomyopathy (HCM) caused by MYBPC3 mutations. The investigational therapy represents Kanghong&#039;s first AAV-based gene therapy product, utilizing an adeno-associated virus (AAV) vector to deliver a functional gene directly to cardiomyocytes, addressing the disease at its genetic root. This regulatory milestone follows U.S. FDA clinical trial approval granted in April 2026, positioning KHN921 as a globally developed gene therapy candidate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70608\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-24T13:11:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-24T13:11:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70608#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70608\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance\",\"datePublished\":\"2026-07-24T13:11:39+00:00\",\"dateModified\":\"2026-07-24T13:11:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70608\"},\"wordCount\":657,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Gene therapy\",\"Kanghong Pharmaceutical\",\"Rare \\\/ orphan disease drugs\",\"SHE: 002773\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70608#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70608\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70608\",\"name\":\"Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-24T13:11:39+00:00\",\"dateModified\":\"2026-07-24T13:11:40+00:00\",\"description\":\"Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced on July 23, 2026 that China's National Medical Products Administration (NMPA) has approved KHN921 for clinical trials in patients with hypertrophic cardiomyopathy (HCM) caused by MYBPC3 mutations. The investigational therapy represents Kanghong's first AAV-based gene therapy product, utilizing an adeno-associated virus (AAV) vector to deliver a functional gene directly to cardiomyocytes, addressing the disease at its genetic root. This regulatory milestone follows U.S. FDA clinical trial approval granted in April 2026, positioning KHN921 as a globally developed gene therapy candidate.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70608#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70608\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70608#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance - Insight, China&#039;s Pharmaceutical Industry","description":"Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced on July 23, 2026 that China's National Medical Products Administration (NMPA) has approved KHN921 for clinical trials in patients with hypertrophic cardiomyopathy (HCM) caused by MYBPC3 mutations. The investigational therapy represents Kanghong's first AAV-based gene therapy product, utilizing an adeno-associated virus (AAV) vector to deliver a functional gene directly to cardiomyocytes, addressing the disease at its genetic root. This regulatory milestone follows U.S. FDA clinical trial approval granted in April 2026, positioning KHN921 as a globally developed gene therapy candidate.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70608","og_locale":"en_US","og_type":"article","og_title":"Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance","og_description":"Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced on July 23, 2026 that China's National Medical Products Administration (NMPA) has approved KHN921 for clinical trials in patients with hypertrophic cardiomyopathy (HCM) caused by MYBPC3 mutations. The investigational therapy represents Kanghong's first AAV-based gene therapy product, utilizing an adeno-associated virus (AAV) vector to deliver a functional gene directly to cardiomyocytes, addressing the disease at its genetic root. This regulatory milestone follows U.S. FDA clinical trial approval granted in April 2026, positioning KHN921 as a globally developed gene therapy candidate.","og_url":"https:\/\/flcube.com\/?p=70608","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-24T13:11:39+00:00","article_modified_time":"2026-07-24T13:11:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70608#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70608"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance","datePublished":"2026-07-24T13:11:39+00:00","dateModified":"2026-07-24T13:11:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70608"},"wordCount":657,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Gene therapy","Kanghong Pharmaceutical","Rare \/ orphan disease drugs","SHE: 002773"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70608#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70608","url":"https:\/\/flcube.com\/?p=70608","name":"Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-24T13:11:39+00:00","dateModified":"2026-07-24T13:11:40+00:00","description":"Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced on July 23, 2026 that China's National Medical Products Administration (NMPA) has approved KHN921 for clinical trials in patients with hypertrophic cardiomyopathy (HCM) caused by MYBPC3 mutations. The investigational therapy represents Kanghong's first AAV-based gene therapy product, utilizing an adeno-associated virus (AAV) vector to deliver a functional gene directly to cardiomyocytes, addressing the disease at its genetic root. This regulatory milestone follows U.S. FDA clinical trial approval granted in April 2026, positioning KHN921 as a globally developed gene therapy candidate.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70608#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70608"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70608#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70608"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70608\/revisions"}],"predecessor-version":[{"id":70610,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70608\/revisions\/70610"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}